Get started
Author

Laura Quintal

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
2025 · Laura A. Huppert, Reshma Mahtani, et al. · npj Breast Cancer · 53
PDF
Abstract PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
2024 · Laura Huppert, Reshma Mahtani, et al. · Cancer Research · 16
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.
2024 · Laura Ann Huppert, Reshma L. Mahtani, et al. · Journal of Clinical Oncology · 14
PDF
Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma
2015 · M. Tan, L. Quintal · Journal of Clinical Pharmacy and Therapeutics · 14
PDF
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer
2023 · Saya Jacob, MacKenzie Johnson, et al. · Clinical Breast Cancer · 9
PDF
Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution’s experience
2015 · Bao D Dao, Hansen Ho, et al. · Journal of Oncology Pharmacy Practice · 5
381P Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience
2024 · K.H. Natsuhara, M. Vella, et al. · Annals of Oncology · 4
PDF
Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer
2025 · Saya Jacob, Samantha Fisch, et al. · npj Breast Cancer · 3
PDF
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer
2025 · Laura A. Huppert, Amelia S. Gliwa, et al. · npj Breast Cancer · 3
PDF
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).
2023 · Laura Ann Huppert, Amelia S Gliwa, et al. · Journal of Clinical Oncology · 3
Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer
2026 · Nikita V. Baclig, Madhuri Chengappa, et al. · Clinical Breast Cancer · 2
Abstract PO4-12-06: Interstitial Lung Disease (ILD) in Sequential Antibody Drug Conjugate (ADC) use in patients with Metastatic Breast Cancer (MBC): A Multi-Institutional experience
2024 · Sarah Premji, Laura Huppert, et al. · Cancer Research · 2
Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study
2025 · Alexis LeVee, Saya Jacob, et al. · Clinical Cancer Research · 1
Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors
2024 · Saya Jacob, Samantha Fisch, et al. · Cancer Research · 1
Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study
2026 · Alexis LeVee, Saya Jacob, et al. · The Breast
PDF
Abstract PS5-05: Late-onset immune toxicity incidence & risk factors in breast cancer: a multi-institutional study
2025 · Saya Jacob, Samantha Fisch, et al. · Clinical Cancer Research
Abstract P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer
2025 · Samantha Fisch, Joshua Chin, et al. · Clinical Cancer Research
Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study
2025 · Nikita Baclig, Andrew Soliman, et al. · Clinical Cancer Research
Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study
2025 · Madhuri Chengappa, Thejaswi K Poonacha, et al. · Clinical Cancer Research
Works count: 19
Citation count: 129
H-index: 5
I10-index: 4
Year
Topic
Type